V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Hologic Executive Compensation (FY24)

HOLX · Executive and director compensation, fiscal 2022 to 2024
Data as of September 7, 2026Latest filing (8-K): February 28, 2025
374 figures on this page: 364 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Total compensation for Stephen MacMillan, Chairman, President and Chief Executive Officer, came to $15,819,261 in fiscal 2024, and MacMillan's total was 1.7% higher than the $15,555,032 reported for fiscal 2023. For fiscal 2024, shareholders backed the say-on-pay proposal with 83.6% of votes cast for or against in favor at the meeting held February 26, 2025. Companies named in the disclosed peer group include Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company and Boston Scientific Corporation, among others. For fiscal 2024, the company reported 5 named executive officers.
Chief executive, fiscal 2024
◇
Stephen MacMillan
Latest say-on-pay support
=
February 26, 2025
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Stephen MacMillan: $15,555,032 → $15,819,261 (1.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Hologic's chief executive and what were they paid?
Total compensation for Stephen MacMillan, Chairman, President and Chief Executive Officer, came to $15,819,261 in fiscal 2024. MacMillan's total was 1.7% higher than the $15,555,032 reported for fiscal 2023.
What was Hologic's say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 83.6% of votes cast for or against in favor at the meeting held February 26, 2025.
Which companies are in Hologic's peer group?
Companies named in the disclosed peer group include Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company and Boston Scientific Corporation, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stephen MacMillan
Chairman, President and Chief Executive Officer
◇—◇◇◇—◇◇
Karleen Oberton
Chief Financial Officer
◇—◇◇◇—◇◇
Kevin Thornal
Group President, Global Diagnostics Solutions
◇—◇◇◇—◇◇
John Griffin
General Counsel
◇———◇—◇— not reconciled
Jan Verstreken
Group President, International
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stephen MacMillan
Chairman, President and Chief Executive Officer
◇—◇◇◇—◇◇
Karleen Oberton
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stephen MacMillan
Chairman, President and Chief Executive Officer
◇—◇◇◇—◇◇
Karleen Oberton
Chief Financial Officer
◇—◇◇◇—◇◇
Essex Mitchell
Chief Operating Officer
◇—◇◇◇—◇◇
Jan Verstreken
Group President, International
◇—◇◇◇—◇◇
John Griffin
General Counsel
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Essex D. MitchellPSU◇◇◇—◇—◇
Essex D. MitchellPSU◇◇◇—◇—◇
Essex D. MitchellRSU◇——◇——◇
Essex D. MitchellPSU◇◇◇—◇—◇
Essex D. MitchellOPTION◇——◇—◇◇
Jan VerstrekenPSU◇◇◇—◇—◇
Jan VerstrekenPSU◇◇◇—◇—◇
Jan VerstrekenOPTION◇——◇—◇◇
Jan VerstrekenRSU◇——◇——◇
Jan VerstrekenPSU◇◇◇—◇—◇
John M. GriffinOPTION◇——◇—◇◇
John M. GriffinRSU◇——◇——◇
John M. GriffinPSU◇◇◇—◇—◇
John M. GriffinPSU◇◇◇—◇—◇
John M. GriffinPSU◇◇◇—◇—◇
Karleen M. ObertonOPTION◇——◇—◇◇
Karleen M. ObertonRSU◇——◇——◇
Karleen M. ObertonPSU◇◇◇—◇—◇
Karleen M. ObertonPSU◇◇◇—◇—◇
Karleen M. ObertonPSU◇◇◇—◇—◇
Stephen P. MacMillanOPTION◇——◇—◇◇
Stephen P. MacMillanPSU◇◇◇—◇—◇
Stephen P. MacMillanPSU◇◇◇—◇—◇
Stephen P. MacMillanRSU◇——◇——◇
Stephen P. MacMillanPSU◇◇◇—◇—◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Stephen MacMillanPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇11/8/2031
Option◇—◇11/9/2030
Option◇—◇11/7/2032
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇11/14/2033
Karleen ObertonPSU◇◇——
RSU◇◇——
Option◇—◇11/14/2033
PSU◇◇——
RSU◇◇——
Option◇—◇11/9/2030
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇11/8/2031
Option◇—◇11/7/2032
John GriffinPSU◇◇——
PSU◇◇——
Option◇—◇11/14/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇11/9/2030
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇11/8/2031
Option◇—◇11/7/2032
Essex MitchellPSU◇◇——
RSU◇◇——
Option◇—◇11/14/2033
Option◇—◇11/7/2032
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇11/8/2031
Option◇—◇11/9/2030
Jan VerstrekenOption◇—◇11/9/2030
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sally W. Crawford
◇◇◇———◇
Amy M. Wendell
Lead independent director
◇◇◇———◇
Charles J. Dockendorff
◇◇◇———◇
Scott T. Garrett
◇◇◇———◇
Nanaz Mohtashami
◇◇◇———◇
Christiana Stamoulis
◇◇◇———◇
Ludwig N. Hantson
◇◇◇———◇
Stacey D. Stewart
◇◇◇———◇
Namal Nawana
◇—————◇
Martin Madaus and Stephen P. MacMillan served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as RSUs and Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Abbott Laboratories ABT
  • Agilent Technologies, Inc. A
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company BDX
  • Boston Scientific Corporation BSX
  • Bruker Corporation BRKR
  • DENTSPLY SIRONA Inc. XRAY
  • DexCom, Inc. DXCM
  • Edwards Lifesciences Corp. EW
  • IDEXX Laboratories, Inc. IDXX
  • Illumina, Inc. ILMN
  • Integra LifeSciences Holdings Corp IART
  • Intuitive Surgical, Inc. ISRG
  • Laboratory Corp. of America Holdings symbol not shown
  • Mettler-Toledo International Inc. MTD
  • Qiagen NV QGEN
  • Quest Diagnostics Inc. DGX
  • ResMed Inc. RMD
  • Revvity, Inc. RVTY
  • STERIS plc STE
  • Stryker Corporation SYK
  • The Cooper Companies, Inc. COO
  • Thermo Fisher Scientific Inc. TMO
  • Waters Corporation WAT
  • Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024February 26, 2025=◇◇◇
2023March 7, 2024=◇◇◇
2022March 9, 2023=◇◇◇
2021March 10, 2022=◇◇◇
2020March 11, 2021=◇◇◇
2019March 5, 2020=◇◇◇
2018March 7, 2019=◇◇◇
2017March 14, 2018=◇◇◇
2016March 8, 2017=◇◇◇
2015March 2, 2016=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Hologic files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Hologic disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Hologic sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Hologic's disclosed peer group is defensible, who names Hologic back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
374 figures on this page: 364 cited to the filing that reported them, 10 calculated from figures it prints.
364 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001140361-25-006521
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001140361-25-001287
    2024 Director Compensation Table · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year End · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0000859737-24-000009
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001140361-24-002733
    Summary Compensation Table
  5. 0000859737-23-000006
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001140361-23-002129
    Director Compensation · Summary Compensation Table
  7. 0000859737-22-000007
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000859737-21-000008
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0000859737-20-000015
  10. 0000859737-19-000008
  11. 0001193125-18-084012
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0000859737-17-000007
  13. 0000859737-16-000049
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Hologic executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/HOLX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Hologic and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Hologic discloses

The companies named in HOLX's own disclosed peer group.

Abbott LaboratoriesAgilent Technologies, Inc.Baxter International Inc.Becton, Dickinson and CompanyBoston Scientific CorporationBruker CorporationDENTSPLY SIRONA Inc.DexCom, Inc.Edwards Lifesciences Corp.Illumina, Inc.Integra LifeSciences Holdings CorpIntuitive Surgical, Inc.Mettler-Toledo International Inc.ResMed Inc.Revvity, Inc.STERIS plcStryker CorporationThe Cooper Companies, Inc.Waters CorporationZimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy